GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » YoY EBITDA Growth

Roquefort Therapeutics (LSE:ROQ) YoY EBITDA Growth : -18.18% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Roquefort Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -18.18%.

Roquefort Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was £-0.01.

Roquefort Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Roquefort Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics YoY EBITDA Growth Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
YoY EBITDA Growth
- - 6.25

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth - - -57.14 80.00 -18.18

Roquefort Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Roquefort Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.015--0.016)/ | -0.016 |
=6.25 %

Roquefort Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.013--0.011)/ | -0.011 |
=-18.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roquefort Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » YoY EBITDA Growth
Comparable Companies
AQSE:PBX LSE:BSFA LSE:BVX LSE:IMM LSE:OCTP LSE:CIZ LSE:IXI LSE:APTA LSE:ONC LSE:VAL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ROQAF:USA
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Website
https://www.roquefortplc.com
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines